Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
J Gore
Publications and source records attributed to J Gore.
Toxicity of insecticides in a glass-vial bioassay to adult brown, green, and southern green stink bugs (Heteroptera: Pentatomidae).
Adult brown, Euschistus servus (Say); green, Acrosternum hilare (Say); and southern green, Nezara viridula (L.), stink bugs were collected from soybean, Glycine max (L.) Merr., in fall 2001 and 2002 near Stoneville, MS, and Eudora, AR. A glass-vial bioassay was used to determine LC50 values for the three species of stink bugs for the pyrethroids bifenthrin, cypermethrin, cyfluthrin, lambda-cyhalothrin, and permethrin, and the organophosphates acephate, dicrotophos, malathion, and methyl parathion. Results confirmed findings of other researchers that the brown stink bug was less susceptible to pyrethroid and organophosphate insecticides than were green and southern green stink bugs. The susceptibility of all three stink bug species to the insecticides tested was very similar at both test locations. The study established baseline insecticide mortality data from two locations in the mid-South for three stink bug species that are pests of soybean and cotton, Gossypium spp. Data from the tests are valuable for future use in studies on resistance and in resistance monitoring programs.
Animals↗
Selective feeding of tobacco budworm and bollworm (Lepidoptera: Noctuidae) on meridic diet with different concentrations of Bacillus thuringiensis proteins.
Laboratory experiments were conducted to evaluate the behavior of bollworm, Helicoverpa zea (Boddie), and tobacco budworm, Heliothis virescens (F.), larvae on meridic diet with different concentrations of the Cry1Ac and Cry2Ab proteins from Bacillus thuringiensis subsp. kurstaki Berliner. The proteins used in these experiments are the ones in commercially available Bollgard and Bollgard II cotton. Both bollworms and tobacco budworms selectively fed on nontreated diet compared with diet treated with Cry1Ac. In addition, bollworms exhibited a concentration response with Cry1Ac. In general, bollworms selected diet with low concentrations of Cry1Ac compared with diet with higher concentrations of Cry1Ac. For Cry2Ab, the avoidance was not as prominent as that observed for Cry1Ac. Based on results from no-choice assays, the Cry1Ac and Cry2Ab concentrations used in choice assays represented a wide range of biological activity on both species. The lower concentrations provided low levels of mortality, whereas the higher concentrations provided high levels of mortality. Also, the developmental times of larvae were longer at higher concentrations of both proteins. These data provide important information about the behavioral response of key cotton pests to the B. thuringiensis proteins found in commercially available transgenic cotton. This information will be important to develop accurate scouting and management procedures for Bollgard and Bollgard II cotton.
Animals↗
Distribution of bollworm, Helicoverpa zea (Boddie), injured reproductive structures on genetically engineered Bacillus thuringiensis var. kurstaki Berliner cotton.
Bollworm, Helicoverpa zea (Boddie), larvae are commonly observed feeding in genetically engineered Bollgard cotton. Although no information is currently available characterizing the levels of injury bollworms cause, aproximately 25% of the Bollgard acreage in the United States receives at least one insecticide application annually targeting bollworm populations. Studies were conducted to determine the levels of fruiting form injury that can occur from bollworm larvae feeding on white flowers of two types of genetically engineered cotton. The two types of genetically engineered cotton included the original Bollgard that produces one protein (Cry1Ac) from Bacillus thuringiensis variety kurstaki Berliner and Bollgard II that produces two proteins (Cry1Ac + Cry2Ab) from B. thuringiensis kurstaki. In one study, individual larvae (24 +/- 6 h old) were placed in first position white flowers of Deltapine 5415 (non-Bollgard) and Deltapine NuCOTN 33B (Bollgard). Larval infestations were made on 50 plants for each of 5 d during 2000 and 2001. Each plant was visually examined at 3 d and every 2 d thereafter, until larvae were no longer recovered. Larvae injured a total of 46.6 fruiting forms per 50 plants on non-Bollgard cotton, compared with only 18.9 fruiting forms per 50 plants on Bollgard cotton. Mean larval injury per insect was 4.3 fruiting forms on non-Bollgard cotton compared with 2.7 fruiting forms on Bollgard cotton. In a second study, individual larvae (24 +/- 6 h old) were placed in first position white flowers of Deltapine 50 (non-Bollgard), Deltapine 50B (Bollgard), and an experimental Bollgard II line. Larval infestations were made on 10 plants per day for each of six consecutive days during 2001. Larvae injured a total of 25.0 fruiting forms per 10 plants on non-Bollgard, 11.5 on Bollgard, and 6.4 on Bollgard II cottons. Mean larval injury per insect was 6.6 fruiting forms on non-Bollgard, 3.5 on Bollgard, and 0.8 on Bollgard II cottons. These data indicate that supplemental insecticide applications may be necessary to prevent yield losses on Bollgard cotton. In contrast, injury to Bollgard II cotton was minimal and may not require additional insecticide applications for bollworms.
Animals↗
Behavior of bollworm (Lepidoptera: Noctuidae) larvae on genetically engineered cotton.
Reports of bollworm, Helicoverpa zea (Boddie), larvae feeding in white flowers of Bollgard cotton have been relatively common since the commercialization of this technology in 1996. Field studies were conducted in Louisiana to determine if differences in bollworm larval behavior occuron non-Bollgard (cultivar 'Deltapine 5415') and Bacillus thuringiensis (Bt), Bollgard ('NuCOTN 33B') cottons. Larvae were placed on the terminal foliage of either single cotton plants or on all plants within 1-m row micro-plots. On preflowering cotton plants, significantly more bollworms moved from the site of infestation (terminal) on Bollgard plants compared with that on non-Bollgard plants. On individual flowering plants, the number of nodes larvae moved from the terminal and the number of infested bolls was greater on Bollgard cotton plants. Similar differences between Bollgard and non-Bollgard plants in the percentage of infested terminals and squares were observed at 48-h after infestation when 1-m rows were infested. These data will be used to refine scouting protocols for bollworm larvae on Bollgard cotton.
Animals↗
Bollworm (Lepidoptera: Noctuidae) survival on 'Bollgard' and 'Bollgard II' cotton flower bud and flower components.
Genetically modified cotton, Gossypium hirsutum L., cultivars ('Bollgard') that produce crystalline proteins from Bacillus thuringiensis (Berliner) are valuable tools for managing lepidopteran insect pests in the United States. However, high numbers of bollworm, Helicoverpa zea (Boddie), larvae have been observed feeding in white flowers of these cultivars. Fresh tissue bioassays were conducted to investigate bollworm survival on Bollgard and 'Bollgard II' cottons. Bollworm survival was higher on square and flower anthers than on other floral structures on 'Deltapine 5415' (conventional cotton) and 'NuCOTN 33B' (Bollgard). Bollworm survival at 72 h was higher on all floral structures from Deltapine 5415 than on corresponding structures from NuCOTN 33B. ELISA tests indicated that CryIA(c) expression varied among plant parts; however, bollworm survival did not correlate with protein expression levels. Trends in bollworm survival on Bollgard II were similar to those on Bollgard and conventional cotton; however, survival was lower on all structures of Bollgard II than on corresponding structures of Bollgard and conventional cotton. These data support field observations of bollworm injury to white flowers and small bolls and provide a better understanding of larval behavior on Bollgard cotton.
Animals↗
Does use of an instant hand sanitizer reduce elementary school illness absenteeism?
Explore the source record for details and available documents.
Absenteeism↗
Frequent attenders in general practice.
Explore the source record for details and available documents.
Data Collection↗
Flocculation and Coalescence of Oil-in-Water Poly(dimethylsiloxane) Emulsions.
The stability of poly(dimethylsiloxane) (PDMS) oil-in-water emulsions has been investigated in the presence of added NaCl as well as in the presence of added surfactant. The emulsions were prepared using a combination of nonionic (C(x)E(y), x and y represent the number of methylene (C) and ethylene oxide (E) groups, respectively) and cationic (quarternary alkylammonium) surfactants. The droplets were observed to exhibit weak flocculation in the presence of high NaCl concentration (1 M). Phase separation and optical microscopic observations revealed that the principal mechanism for emulsion destabilization at high salt concentration was coalescence, which was accelerated at elevated temperature (50 degrees C). The effective coalescence rate for diluted emulsions was investigated using photon correlation spectroscopy. The small effective Hamaker constant for PDMS is the primary reason for the slow rate of coalescence observed for the emulsions at neutral pH in the presence of NaCl. The stability of PDMS emulsions to flocculation is qualitatively similar to that reported for low Hamaker constant dispersions (e.g., microgel particles). Addition of cationic surfactants (cetyltrimethylammonium chloride and dodecyl dimethylbenzylammonium chloride) to the negatively charged droplets after preparation was shown to decrease the emulsion stability once the surfactant concentration exceeded the CMC. Electrophoretic mobility measurements showed that added cationic surfactant changed the sign of the droplet charge from negative to positive at concentrations well below the CMC. Charged micelles of the same sign as the droplets are electrostatically excluded from close approach to the droplet surface within a distance (varepsilon) which results in depletion flocculation. Copyright 2000 Academic Press.
Journal Article↗
Cotton boll abscission and yield losses associated with first-instar bollworm (Lepidoptera: Noctuidae) injury to nontransgenic and transgenic Bt cotton.
Field tests were conducted in northeastern Louisiana to determine the effects of infestations by Helicoverpa zea (Boddie) on cotton bolls of varying ages. First instars were caged on bolls of nontransgenic ('Deltapine 5415') or transgenic Bacillus thuringiensis Berliner variety kurstaki (Bt) ('NuCOTN 33B') cotton from 29 June to 11 August during 1997 and 1998. Deltapine 5415 bolls that accumulated 179 (7.2 d), 281 (11.2 d), and 253 (10.1 d) heat units beyond anthesis were safe from bollworm-induced abscission at 72 h after infestation, 7 d after infestation, and at the time of harvest, respectively. NuCOTN 33B bolls that accumulated 157 (6.3 d), 185 (7.4 d), and 180 (7.2 d) heat units beyond anthesis were safe from bollworm-induced abscission at 72 h after infestation, 7 d after infestation, and at the time of harvest, respectively. Bollworm larvae reduced seedcotton weights of Deltapine 5415 bolls that accumulated between 58.5 (2.3 d) and 350.5 (14.0 d) heat units beyond anthesis. Seedcotton weights of NuCOTN 33B bolls that accumulated between 0 and 281 (11.2 d) heat units beyond anthesis were reduced by bollworm injury. Deltapine 5415 and NuCOTN 33B bolls that accumulated 426.5 (17.1 d) and 299.5 (12.0 d) heat units beyond anthesis, respectively, before infestation were not injured by first-instar bollworm larvae. These data provide information about late-season insecticide termination strategies for bollworms on nontransgenic and transgenic Bt-cotton. This, in turn, will help pest managers determine when insecticides are no longer economical during the late season.
Animals↗
A thioester analogue of an amino acetylenic aldehyde is a suicide inhibitor of aldehyde dehydrogenase and an inducer of apoptosis in mouse lymphoid cells overexpressing the bcl2 gene.
Explore the source record for details and available documents.
Aldehyde Dehydrogenase↗
Gene therapy expression vectors based on the clotting Factor IX promoter.
The liver is one of the prime targets for gene therapy, and the correction of defects in a variety of clotting factor genes is one of the main goals of liver-directed therapies. The use of transcriptional regulatory elements derived from these genes may provide for the optimal expression of transduced genes. We have applied our knowledge of the promoter structure of the clotting Factor IX gene to design optimized expression vectors for use in gene therapy. The activity of the proximal promoter has been augmented by the introduction of a multimerized upstream site which we have previously shown to be a prime regulator of the pro- moter. Introduction of this element increases promoter activity at least 20-fold over the proximal promoter alone when assayed in the human liver cell line Hep G2. This optimized promoter is significantly more active than the SV40 enhancer/early promoter. The expression of the optimized Factor IX promoter is also more persistent in the short term. The inclusion of a liver-specific locus control region, derived from the apolipoprotein E/C locus, did not further augment expression levels. These Factor IX vectors also exhibit a high degree of tissue specificity, as measured by transfection into breast and muscle cell lines.
Cell Line↗
Experimental AA amyloidogenesis is associated with differential expression of extracellular matrix genes.
An abnormality in basement membrane metabolism has been postulated to play an important role in the pathogenesis of experimental murine AA amyloidosis. The potential contribution of the structural basement membrane proteins laminin, type IV collagen and entactin to amyloidogenesis in this model was investigated with a kinetic analysis of the expression of the corresponding genes during amyloid formation. Splenic AA amyloid deposition was stimulated by the concomitant administration of subcutaneous silver nitrate, as an inflammatory stimulus, and intravenous amyloid enhancing factor. Using a reverse transcription-polymerase chain reaction assay, a differential pattern of expression of these genes was observed at the mRNA level. Whereas laminin B1 mRNA levels did not change at any time during amyloidogenesis, a 2.2 to 3 fold induction of laminin B2, entactin and alpha 1-type IV collagen mRNAs coincided with the initial detection of splenic amyloid deposits at 48 hours post-stimulation, as detected by immunohistochemistry. Temporal and spatial codeposition of laminin and type IV collagen with amyloid was demonstrated by immunohistochemistry. A 1.4, 2.3 and 2.2-fold increase in laminin B2, entactin and alpha 1-type IV collagen mRNA levels, respectively, was detected at 24 hours post-stimulation, a point at which amyloid deposits could not be detected. Neither inflammation nor amyloid enhancing factor alone influenced laminin, entactin or type IV collagen expression at the protein or mRNA level. These observations suggest that the laminin B2 chain and alpha 1-type IV collagen chain account, at least in part, for the observed laminin and collagen IV immunoreactivity in AA amyloid deposits and that entactin may also be a component of the amyloid deposit. The onset of the induction of laminin B2, entactin and alpha 1-type IV collagen gene expression prior to the appearance of amyloid deposits, and our previous data with the heparan sulfate proteoglycan, perlecan, suggests these basement membrane proteins may play a role in the initial stages of AA fibrillogenesis.
Amyloid↗
Developing, validating and consolidating the doctor-patient relationship: the patients' views of a dynamic process.
BACKGROUND: Previous research has examined the doctor-patient relationship in terms of its therapeutic effect, the need to consider the patients' models of their illness, and the patients' expectations of their doctor. However, to date, no research has examined the patients' views of the doctor-patient relationship. AIM: To examine patients' views of the process of creating a relationship with their general practitioner (GP). METHOD: A qualitative design was used involving in-depth interviews with 27 frequently attending patients from four urban general practices. They were chosen to provide a heterogeneous group in terms of age, sex, and ethnicity. RESULTS: The responders described creating the relationship in terms of three stages: development, validation, and consolidation. The development stage involved overcoming initial reservations, actively searching for a doctor that met the patient's needs, or knowing from the start that the doctor was the right one for them. The validation stage involved evaluating the nature of the relationship by searching for evidence of caring, comparing their doctor with others, storing key events for illustration of the value of the relationship, recruiting the views of others to support their own perspectives, and the willingness to make tradeoffs. The consolidation stage involved testing and setting boundaries concerned with knowledge, power, and a personal relationship. CONCLUSION: Creating a relationship with a GP is a dynamic process involving an active patient who searches out a GP who matches their own representation of the 'ideal', selects and retains information to validate their choice, and locates mutually acceptable boundaries.
Adult↗
Health insurance coverage and outcome following acute myocardial infarction. A community-wide perspective.
BACKGROUND: Several studies have suggested that type of medical insurance coverage is associated with hospital utilization rates and receipt of selected diagnostic or treatment approaches. To our knowledge no studies, however, have examined the relation between medical insurance coverage and short-term outcomes following acute myocardial infarction (AMI) from a multihospital, community-wide perspective. OBJECTIVE: To examine the association between medical insurance coverage and in-hospital case-fatality rates as well as length of hospital stay following AMI. METHODS: The study sample consisted of 3735 residents of the Worcester, Mass, metropolitan area hospitalized with validated AMI during 1986, 1988, 1990, 1991, and 1993 at all metropolitan Worcester hospitals. Data were obtained from the review of medical records. Patients were stratified into 5 medical insurance groups for purposes of analysis: private or commercial (n = 711), Medicaid (n = 101), Medicare (n = 1991), health maintenance organization (n = 741), and self-pay or other (n = 191). Crude and multivariable-adjusted analyses were used to examine the relation between medical insurance coverage and length of hospital stay and in-hospital case-fatality rates following AMI. RESULTS: In-hospital case-fatality rates during the period under study were 7.7%, 11.9%, 21.4%, 9.3%, and 10.0% in the 5 medical insurance groups, respectively. After adjusting for several factors that may affect in-hospital mortality, relative to the referent group of private or commercial insurance patients (odds ratio, 1.0), the multivariable-adjusted odds for dying during the acute hospitalization were 0.87 (95% confidence interval [CI], 0.56-1.36) for health maintenance organization patients, 1.22 (95% CI, 0.55-2.68) for Medical patients, 1.25 (95% CI, 0.85-1.84) for Medicare patients, and 1.21 (95% CI, 0.60-2.44) for self-pay or other patients. The mean length of hospitalization after excluding patients with a prolonged hospitalization was 10.1 days for private or commercial insurance patients, 9.4 days for health maintenance organization patients, 10.9 days for Medicaid patients, 11.1 days for Medicare patients, and 9.8 days for self-pay or other patients. No significant differences in the average duration of hospitalization were seen between the medical insurance groups after controlling for potential confounding variables. CONCLUSIONS: The results of this population-based study suggest that patient insurance status is not significantly associated with either length of hospital stay or short-term mortality following AMI. Other demographic and clinical prognostic factors appear to be more important predictors of short-term outcome in this patient population.
Adult↗
Infrequent events transiently activate human prefrontal and parietal cortex as measured by functional MRI.
P300 is an event-related potential elicited by infrequent target events whose amplitude is dependent on the context provided by the immediately preceding sequence of stimuli, suggesting its dependence on working memory. We employed magnetic resonance imaging sequences sensitive to blood oxygenation level to identify regional changes evoked by infrequent visual target stimuli presented in a task typically used to elicit P300. Targets evoked transient event-related activation bilaterally in the middle frontal gyrus, in the inferior parietal lobe, and near the inferior aspect of the posterior cingulate gyrus beginning within 1.5 s of target onset and peaking between 4.5 and 6 s. These regions have been identified in previous neuroimaging studies in humans, and in single-unit recordings in monkeys, as components of a neural system mediating working memory, which suggests that this system may be activated by the same events that evoke P300.
Adult↗
Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: a community-wide perspective.
In spite of national interest in gender differences in the presentation and management of chronic disease, limited information is available about possible gender differences in the receipt of thrombolytic therapy after acute myocardial infarction (AMI). As part of an ongoing community-based study of AMI, we examined gender differences in the receipt of thrombolytic therapy among 2885 patients with confirmed AMI. The study sample consisted of 1680 males and 1205 females with validated AMI who were admitted to 16 hospitals in the Worcester, Massachusetts, metropolitan area in four study periods between 1986 and 1991. During the years under study, 24.4% of men and 14.4% of women received thrombolytic therapy. Increases over time in the use of thrombolytic therapy were seen in both men (13.9% in 1986; 31.6% in 1991) and women (3.2% in 1986; and 19.0% in 1991). After controlling for a variety of factors that might affect use of thrombolytic agents, younger age, absence of a history of either congestive heart failure or stroke, and experiencing a Q-wave AMI were associated with receipt of thrombolytic therapy in both men and women; having an anterior AMI also was associated with use of thrombolytic agents in men. Women without as compared with those with a history of angina pectoris were significantly more likely to receive thrombolytics. Men who had Medicare insurance were significantly less likely to receive thrombolytics than were men with other types of health insurance. When this analysis was restricted to patients who were seen in area-wide hospitals within 6 hours of the onset of symptoms suggestive of AMI, similar factors were associated with the receipt of thrombolytic agents in men and women. The results of this community-wide study suggest a marked increase over the 5-year study period in the use of thrombolytic therapy in both men and women, with a greater relative increase observed in women. A relatively similar profile of patients likely to receive thrombolytic therapy was seen in both men and women.
Age Factors↗
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.
Parenchymatous intracerebral hemorrhage (ICH) is a serious, infrequent complication of thrombolytic therapy for acute myocardial infarction. We studied the clinical and radiologic features, manner of presentation, associated factors, and temporal course in 23 patients with ICH associated with 150 mg or 100 mg recombinant tissue-type plasminogen activator (rt-PA) and heparin therapy for acute myocardial infarction in the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial. In TIMI II, 13 of the 23 ICH patients developed or maintained systolic blood pressure > or = 160 mm Hg or diastolic blood pressure > or = 90 mm Hg during the rt-PA infusion and before the onset of neurologic symptoms. Six patients (26%) had life-threatening ventricular arrhythmias, five before onset of neurologic symptoms. A decreased level of consciousness was the earliest neurologic abnormality in 15 (65%) and the most common initial physical finding (in 19, or 82%). Onset was usually gradual (70%), but time to maximal deficit was frequently (61%) within 6 hours of onset. The locations of the primary ICH sites were lobar in 16 (70%), thalamic in four (17%), and brainstem-cerebellum in three (13%), but the putamen was never the primary site. Multiple lobar hemorrhages occurred in six cases (26%). The timing and size of ICH was similar among patients treated with 150 mg rt-PA and 100 mg rt-PA. Brain CT demonstrated an arteriovenous malformation in one case. Four patients had hypofibrinogenemia, which was profound in three patients. Pathologic findings were available for five patients. Of these, three patients had cerebral amyloid angiopathy, and one had hemorrhagic transformation of an ischemic cerebral infarction found at autopsy. We conclude that ICH following rt-PA and heparin therapy for acute myocardial infarction presents as a distinctive clinical syndrome. Intracerebral bleeding after combined thrombolytic and antithrombotic therapy may be associated with cerebral amyloid angiopathy and other vascular lesions. Acute or persistent hypertension before or during rt-PA infusion, life-threatening ventricular arrhythmias, and hypofibrinogenemia, either alone or in combination, may play roles in some cases. Care should be exercised when considering thrombolytic therapy for patients with risk factors for ICH.
Adult↗